Phase II Study of Personalized Proton Beam Therapy Planning for Adults with Low-Grade Glioma to Reduce Brain Side Effects

What this Trial Is About

Low-grade glioma LGG are typically slow-growing brain tumors classified as WHO grade I or II, commonly affecting young adults around their forties. This trial investigates the feasibility of using individualized, model-guided optimization of proton beam treatment planning to reduce late brain lesions and long-term side effects. The study focuses on improving radiotherapy timing and planning to avoid complications like neurocognitive impairment and secondary tumors while maintaining disease control. Participants receive proton beam radiotherapy with either a standard treatment plan or an optimized plan guided by a model calculating normal tissue complication probability NTCP. The optimization uses advanced software to minimize risks of late contrast-enhancing brain lesions CEBL by adjusting dose distributions based on predicted biological effects. The study involves two randomized groups one with standard treatment plans and one with model-optimized plans, with no further changes after plan approval. Throughout the 24 months following treatment, participants undergo quarterly MRI scans to monitor for brain lesions and tumor progression. Researchers also assess radiation-induced brain injuries, survival outcomes, patient-reported experiences, and quality of life using specific questionnaires. This comprehensive follow-up is designed to evaluate the benefits and safety of model-guided treatment planning in improving long-term outcomes for patients with low-grade glioma.

Feasibility of Individualized, Model-guided Optimization of Proton Beam Treatment Planning in Patients With Low Grade Glioma